Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress

被引：0
|
作者：
Paik, P. [1 ]
Sakai, H. [2 ]
Bruns, R. [3 ]
Scheele, J. [4 ]
Straub, J. [5 ]
Felip, E. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan
[3] Merck KGaA, Biostat, Darmstadt, Germany
[4] Merck KGaA, Clin Oncol, Darmstadt, Germany
[5] Merck KGaA, Global Early Dev, Darmstadt, Germany
[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
546TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer
    Wu, Xue
    Zhang, Yaru
    Pang, Jiaohui
    Lin, Li
    Yin, Jiani C.
    Tang, Haimeng
    Shao, Yang
    CANCER RESEARCH, 2023, 83 (07)
  • [32] Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
    Spira, A.
    Krebs, M.
    Cho, B. C.
    Besse, B.
    Goldman, J.
    Janne, P.
    Lee, C. K.
    Ma, Z.
    Mansfield, A.
    Minchom, A.
    Ou, S.
    Salgia, R.
    Wang, Z.
    Gao, G.
    Curtin, J.
    Roshak, A.
    Schnepp, R.
    Thayu, M.
    Knoblauch, R.
    Trigo, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S874 - S875
  • [33] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [34] Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy.
    McKenzie, Andrew
    Fisher, Arielle
    Correll, Mick
    Jones, Carissa
    Correia, Jessica
    Thurber, James
    Misch, Amanda
    Heritage, Jessica
    Sturgill, Emma
    Jones, Suzanne Fields
    Johnson, Melissa Lynne
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations (METex14).
    Yu, Yongfeng
    Ren, Yongxin
    Fang, Jian
    Cao, Lejie
    Liang, Zongan
    Guo, Qisen
    Han, Sen
    Ji, Zimei
    Wang, Ye
    Sun, Yulan
    Chen, Yuan
    Li, Xingya
    Xu, Hua
    Zhou, Jianying
    Jiang, Liyan
    Cheng, Ying
    Han, Zhigang
    Shi, Jianhua
    Chen, Gongyan
    Ma, Rui
    Fan, Yun
    Sun, Sanyuan
    Jiao, Longxian
    Jia, Xiaoyun
    Wang, Linfang
    Lu, Puhan
    Li, Jing
    Xu, Qian
    Luo, Xian
    Su, Weiguo
    Lu, Shun
    CANCER RESEARCH, 2021, 81 (13)
  • [36] Cytomorphology of Non-Small Cell Lung Carcinoma with MET Exon 14 Skipping Mutations
    Labiano, Tania
    Echegoyen, Ana
    Moneo, Marta
    Elizalde, Jesus
    Guerrero, David
    LABORATORY INVESTIGATION, 2024, 104 (03) : S438 - S439
  • [37] BUDGET IMPACT ANALYSIS OF TEPOTINIB IN ENGLAND FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    McLean, T.
    Alexopoulos, S.
    Hook, E.
    Batterson, R.
    Vioix, H.
    VALUE IN HEALTH, 2022, 25 (12) : S143 - S143
  • [38] MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations
    Jorgensen, Jan Trost
    Urbanska, Edyta M.
    Mollerup, Jens
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (04) : 940 - 946
  • [39] Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
    Smit, E. F.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Le, X.
    Veillon, R.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Thomas, M.
    Viteri Ramirez, S.
    Berghoff, K.
    Bruns, R.
    Otto, G. P.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1002 - S1003
  • [40] Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.
    Palk, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Scheele, Jurgen
    Bruns, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345